Breast Cancer Res Treat (2018) 168:57–67 https://doi.org/10.1007/s10549-017-4570-4 CLINICAL TRIAL Serial immunological parameters in a phase II trial of exemestane and low‑dose oral cyclophosphamide in advanced hormone receptor‑positive breast cancer 1 1 1 1 2 1 1 Maryann Kwa · Xiaochun Li · Yelena Novik · Ruth Oratz · Komal Jhaveri · Jennifer Wu · Ping Gu · 1 1 1 1 1 3 Marleen Meyers · Franco Muggia · James Speyer · Alyssa Iwano · Maryam Bonakdar · Lina Kozhaya · 1 1 1 1 1,3 1 Ece Tavukcuoglu · Bahar Budan · Roy Raad · Judith D. Goldberg · Derya Unutmaz · Sylvia Adams Received: 18 October 2017 / Accepted: 4 November 2017 / Published online: 9 November 2017 © Springer Science+Business Media, LLC, part of Springer Nature 2017 Abstract responses were seen in 6/23 patients (26.1%; 95% CI 10.2– Background and purpose Resistance to endocrine thera- 48.4%) and were durable (median 11.6 months). Three- pies in hormone receptor (HR)-positive breast cancer is a month PFS rate was 50.1% (95% CI 33.0–76.0%); median significant challenge. Prior studies have shown that low-dose PFS was 4.23 months (95% CI 2.8–11.7). No treatment- oral cyclophosphamide can transiently deplete regulatory T related decrease in Tregs was observed. However, elevated cells (Tregs) and improve anti-tumor immunity. We inves- baseline levels of Naïve Tregs [greater than 2.5 (the median
Breast Cancer Research and Treatment – Springer Journals
Published: Nov 9, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera